Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by Mugen1996on May 14, 2008 6:47pm
129 Views
Post# 15074623

Conference Call Tomorrow morning

Conference Call Tomorrow morning

I hope this is good!

May 14, 2008

Notice of Conference Call & Media Advisory

Theratechnologies signs a strategic agreement to explore the use of tesamorelin in an additional indication

Montréal, Canada, May 14, 2008 - Theratechnologies (TSX:TH) advises of an upcoming conference call and webcast to discuss the signing of a strategic agreement to explore the use of tesamorelin in an additional indication.The call will be moderated by Dr. Andrea Gilpin, Executive Director, IR & Communications, at Theratechnologies. Mr. Yves Rosconi, President and CEO, Dr. Pierre Caudrelier, Chief Medical Officer and Dr. Christian Marsolais, Vice President, Clinical Research, will also be participating.

The conference call will take place tomorrow, May 15, at 8:00 a.m. Eastern Time. Prior to the call, a press release will be issued at approximately 7:00 a.m.

May 15, 2008 conference call and webcast
For the conference call, interested participants are asked to dial the following numbers:
416-915-5765 or 1-800-814-4862 (toll free). Please call five minutes prior to the conference in order to ensure your participation. The webcast will be available on the Company's website at https://www.theratech.com/.

A replay of the conference call will be available from May 15, 2008 at 10:00 a.m. to May 22, 2008 at 11:59 p.m. at the following number: 416-640-1917, pass code 21272300# or
1-877-289-8525, code 21272300#. The webcast will be posted for 30 days on the Company's website.

Bullboard Posts